≡ Menu

New FDA-Approved Stent to Treat Coronary Artery Disease Now Available

Baylor Scott & White – Round Rock is first hospital in Williamson County to offer new option for patients with heart disease

It’s estimated that 15 million Americans suffer from coronary artery disease (CAD). This week, Baylor Scott & White Medical Center – Round Rock was the first hospital in Williamson County to implant a new bioabsorbable polymer drug-eluting stent approved by the U.S. Food and Drug Administration.

This new option will help heart patients with chronic or recurring CAD, a result of plaque buildup in arteries that could lead to a heart attack or stroke. Drug-eluting stents are metal “scaffolds” that have been coated with a drug and are known to suppress the re-blocking or closing up of an artery after angioplasty.

Cardiologists at Baylor Scott & White Medical Center – Round Rock implanted the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES), which gives heart disease patients an effective long-term treatment option.

“This new stent system features a drug coating and polymer that are absorbed by the body after delivering the drug to the artery. The platinum chromium body is covered with a medicated coating that dissolves after the medication is finished dispensing over a three-month period. It is designed to enable more rapid healing, thereby reducing the risk of complications associated with long-term polymer exposure,” said Vijay Divakaran, MD, cardiologist, Baylor Scott & White – Round Rock.

Unlike previous drug-coated stents, this new coating is applied only to the exterior of the stent. This helps to limit the patient’s body’s exposure to foreign substances, like polymers, that can trigger inflammation. Long-term exposure to polymers can be associated with stent thrombosis or the formation of a blood clot near the stent, and formation of scar tissue in the coronary artery.

Comments on this entry are closed.